Eligo Bioscience - About the company
Eligo Bioscience is a series B company based in Paris (France), founded in 2014 by and . It operates as a Developer of microbiome gene therapies against infectious disease. Eligo Bioscience has raised $52.3M in funding from investors like Khosla Ventures, Seventure Partners and Sanofi Ventures. The company has 224 active competitors, including 89 funded and 34 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Tessera Therapeutics.
Company Details
Developer of microbiome gene therapies against infectious disease. It offers CRISPR-based gene therapy to treat Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome. It has a properitery platform Gene Editing of the Microbiome that modulates the microbiome鈥檚 composition and function.
- Website
- Social
- Email ID
- @eligo-bioscience.com
Key Metrics
Founded Year
2014
Location
Paris, France
Stage
Series B
Total Funding
in 7 rounds
Latest Funding Round
Investors
Ranked
14th among
Similar Companies
Get your free copy of Eligo Bioscience's company profile
Eligo Bioscience's funding and investors
Eligo Bioscience has raised a total funding of $52.3M over 7 rounds. Its first funding round was on Jul 08, 2015. Its latest funding round was a Grant (prize money) round on May 13, 2025 for $5M. 1 investor participated in its latest round, which include Seventure Partners, Sanofi Ventures, Khosla Ventures and Bpifrance.
Eligo Bioscience has 7 institutional investors including Khosla Ventures, Seventure Partners and Sanofi Ventures.
Here is the list of recent funding rounds of Eligo Bioscience:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
May 13, 2025 | $5M | Grant (prize money) | 9745429 | 1969131 | |
Nov 05, 2023 | $30.1M | Series B | 2801747 | 2675575 | Sanofi Ventures, Bpifrance, and |
Mar 31, 2022 | $55.7K | Grant (prize money) | 2391839 | 1386506 |
Access funding benchmarks and valuations. Sign up today!View details of Eligo Bioscience's funding rounds and investors
Eligo Bioscience's founders and board of directors
The founders of Eligo Bioscience are and . is the CEO of Eligo Bioscience.
Here are the details of Eligo Bioscience's key team members:
- : Co-Founder of Eligo Bioscience and founder of . Contact Info:
- : Co-Founder & CEO of Eligo Bioscience. Contact Info:
View details of
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Eligo Bioscience's Competitors and alternates
Top competitors of Eligo Bioscience include Beam Therapeutics, eGenesis and Tessera Therapeutics. Here is the list of Top 10 competitors of Eligo Bioscience, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | BB Biotech, HTIF听&补尘辫;听 | 69/100 |
2nd | eGenesis 2015, Cambridge (United States), Series D | Developer of a gene transplantation platform for humanizing pig cells | $481M | 68/100 | |
3rd | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | Foresite Capital, T. Rowe Price听&补尘辫;听 | 64/100 |
4th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA-editing technologies for precision medicine | $4M | Citadel, New Enterprise Associates听&补尘辫;听 | 63/100 |
5th | Insmed 1999, Bridgewater (United States), Public | Developer of small molecule inhibitors for rare lung diseases | - | 62/100 | |
6th | Aridis Pharma 2005, San Jose (United States), Public | Provider of human monoclonal antibodies against infectious diseases | $42.1M | , 听&补尘辫;听 | 59/100 |
7th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 59/100 | |
8th | _1551769784760.png?height=40&width=40){kind=logo} Rejuvenate Bio 2017, San Diego (United States), Series A | Developer of a gene-editing platform and anti-aging therapy for dogs | $14.6M | VCapital, Companion Fund听&补尘辫;听 | 59/100 |
9th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | Hercules Capital, 听&补尘辫;听 | 58/100 |
10th |  Mammoth 2017, San Francisco (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 57/100 | |
14th |  2014, Paris (France), Series B | Developer of microbiome gene therapies against infectious disease | $52.3M | Seventure Partners, Sanofi Ventures听&补尘辫;听 | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Eligo Bioscience's competitors? Click to see the top ones
Eligo Bioscience's Investments and acquisitions
Eligo Bioscience has made no investments or acquisitions yet.
Reports related to Eligo Bioscience
Here is the latest report on Eligo Bioscience's sector:
View
News related to Eligo Bioscience
Media has covered Eligo Bioscience for a total of 2 events in the last 1 year.
鈥�
鈥�
PR Newswire鈥�May 13, 2025鈥�Eligo Bioscience
鈥�
鈥�
鈥�
Pharmaceutical Business Review鈥�Oct 12, 2022鈥�Eligo Bioscience
鈥�
鈥�
CMOCRO鈥�Sep 17, 2019鈥�Eligo Bioscience
鈥�
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Eligo Bioscience
Explore our recently published companies
- First General DM - Edmonton based, Unfunded company
- Persol - Angers based, 2015 founded, Unfunded company
- Go Services - Canada based, Unfunded company
- Briede Family Vineyards - Winchester based, 2013 founded, Funding Raised company
- bostonfirealarm - Unfunded company
- Vermon - Tours based, 1984 founded, Funding Raised company
